Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background The most suitable antihypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients.Methods As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment. Mean age of patients was 67 years (SD 7) and mean blood pressure 177/96 mm Hg (14/10) after placebo run-in. We followed up patients for at least 4 years (mean 4.7 years [1.1]). We used Cox regression analysis with baseline Framingham risk score and electrocardiogram-LVH as covariates to compare the effects of the drugs on the primary composite endpoint of cardiovascular morbidity and mortality (cardiovascular death, stroke, or myocardial infarction).Findings Mean blood pressure fell to 146/79 mm Hg (17/11) in losartan patients and 148/79 mm Hg (19/11) in atenolol patients. The primary endpoint occurred in 103 patients assigned losartan (n=586) and 139 assigned atenolol (n=609); relative risk 0.76 (95% CI 0.58-.98), p=0.031. 38 and 61 patients in the losartan and atenolol groups, respectively, died from cardiovascular disease; 0.63 (0.42-0.95), p=0.028. Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0.61 (0.45-0.84), p=0.002.Interpretation Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH. Losartan seems to have benefits beyond blood pressure reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All available BP-lowering drugs can be used, but evidence strongly supports using a renin-angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in patients with evidence of end-organ damage (albuminuria and left ventricular [LV] hypertrophy).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [213]
In the citing paper
“In patients with congestive heart failure (CHF), including diabetic subgroups, ARBs have been shown to reduce major CVD outcomes (175–178), and in type 2 patients with significant nephropathy, ARBs were superior to calcium channel blockers for reducing heart failure (179–181).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [178]
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Self-citationDahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
(2000) · PubMed · Cited by 2,095
Research works printed but not linked: 2
- Liu, 2000, Cardiovascular disease and prognosis in adults with glucose disorders: the Strong Heart Study, J Am Coll Cardiol, 35, 263A
- 2002, Diabetic nephropathy, Diabetes Care, 25, S85
Cited by
Items 701–800 of 1,001
Treatment of diabetic nephropathy in its early stages
Deferrari, G., Ravera, M., & Berruti, V. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.363 · Cited by 18
Nash, D. T. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e318038174e · Cited by 15
Resnick, L. M., Catanzaro, D., Sealey, J. E., & Laragh, J. H. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.12.003 · Cited by 16
Traitement médicamenteux du diabète de type 2recommandation de bonne pratique
(2007) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)80038-3 · Cited by 20
Terpenoids in Diabetic Nephropathy: Advances and Therapeutic Opportunities
Kaushik, M., Kaushik, A., Chaudhary, J., & Jain, A. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230901164219 · Cited by 14
Endothelin Antagonism in Patients with Resistant Hypertension and Hypertension Nephropathy
Lazich, I., & Bakris, G. L. (2011) · Contributions to nephrology · doi:10.1159/000328988 · Cited by 21
Preston, R. A., Karim, A., Dudkowski, C., Zhao, Z., Garg, D. C., Lenz, O., & Sica, D. A. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0044-y · Cited by 14
Ye, Y., Keyes, K. T., Zhang, C. F., Perez-Polo, J. R., Lin, Y., & Birnbaum, Y. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6227-y · Cited by 14
Sheikh‐Ali, M., Raheja, P., & Borja‐Hart, N. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.01.2621 · Cited by 16
Gilbert, R. E., Rabi, D. M., Larochelle, P. M., Leiter, L. A., Jones, C., OGILVIE, R. I., Tobe, S. W., Khan, N. A., Poirier, L., & Woo, V. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.033 · Cited by 17
Blood pressure targets for hypertension in patients with type 2 diabetes
Aronow, W. S., & Shamliyan, T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.36 · Cited by 18
Role of the fixed-dose combination lercanidipine–enalapril in renal protection
Egan, C. G., & Pontremoli, R. (2011) · Journal of Nephrology · doi:10.5301/jn.2011.6271 · Cited by 14
Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine
Tocci, G., Palano, F., Pagannone, E., Chin, D., Ferrucci, A., & Volpe, M. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.7.2.115 · Cited by 14
Primary care diabetes bundle management: 3-year outcomes for microvascular and macrovascular events.
Bloom, F. J., Yan, X. S., Stewart, W. F., Graf, T. R., Anderer, T., Davis, D. E., Pierdon, S. B., Pitcavage, J. M., & Steele, G. D. (2014) · PubMed · Cited by 15
Lee, S., Sung, J. M., Cho, I., Kim, H. C., & Chang, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195459 · Cited by 21
Wang, G., Chen, Y., Li, L., Tang, W., & Wright, J. M. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0066-x · Cited by 16
McMahon, L. P. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16029.x · Cited by 16
Smebye, M. L., Iversen, E. K., Høieggen, A., Flaa, A., Os, I., Kjeldsen, S. E., Olsen, M. H., Chattopadhyay, A., Hille, D. A., Lyle, P. A., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.109 · Cited by 14
Self-citationAntihypertensive treatment and prevention of stroke and dementia
WANG, J., Staessen, J. A., & Birkenhäger, W. H. (2003) · Seminars in Cerebrovascular Diseases and Stroke · doi:10.1053/j.scds.2003.00.025 · Cited by 16
Prompt, Aggressive BP Lowering in High‐Risk Patients
Jamerson, K., & BASILE, J. N. (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2007.08145.x · Cited by 16
Bommer, W. J. (2008) · Preventive Cardiology · doi:10.1111/j.1751-7141.2008.08435.x · Cited by 14
Hropot, M., Langer, K. H., Wiemer, G., Grötsch, H., & Linz, W. (2003) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-002-0682-3 · Cited by 14
Salmasi, A.-M., Jepson, E., Grenfell, A., Kirollos, C., & Dancy, M. C. (2003) · Angiology · doi:10.1177/000331970305400606 · Cited by 14
Tocci, G., Sciarretta, S., Facciolo, C., & Volpe, M. (2007) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.5.4.767 · Cited by 14
1 (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)70618-4 · Cited by 16
The patient with diabetes: Preventing cardiovascular complications
Heinig, R. E. (2009) · Clinical Cardiology · doi:10.1002/clc.4960291404 · Cited by 15
Jugdutt, B. I., & Menon, V. (2004) · Molecular and Cellular Biochemistry · doi:10.1023/b:mcbi.0000038236.59905.8b · Cited by 16
Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease
Andersen, N. H., & Mogensen, C. E. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0056-y · Cited by 14
The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease
Kalantarinia, K., & Okusa, M. D. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0045-4 · Cited by 13
Preventing Dementia by Treating Hypertension and Preventing Stroke
Spence, J. D. (2004) · Hypertension · doi:10.1161/01.hyp.0000132374.90924.2a · Cited by 15
Benefits of blood pressure reduction in diabetic patients
Ball, S. G. (2003) · Journal of Hypertension · doi:10.1097/00004872-200307006-00006 · Cited by 16
Infective endocarditis--an Indian perspective.
Ss, K., Ramakrishnan, S., & Vk, B. (2005) · PubMed · Cited by 16
Fogari, R., Zoppi, A., Mugellini, A., Maffioli, P., Preti, P. S., & Derosa, G. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.683175 · Cited by 18
Hasegawa, H., Takano, H., Kameda, Y., Kubota, A., Kobayashi, Y., & Komuro, I. (2012) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2011.628729 · Cited by 14
Kim, J. H., Oh, S. J., Lee, J. M., Hong, E. G., Yu, J. M., Han, K. A., Min, K. W., Son, H. S., & Chang, S. A. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.3.236 · Cited by 14
Pathophysiology of Primary Hypertension
Carey, R. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374530-9.00020-6 · Cited by 17
Flack, J. M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01577.x · Cited by 14
Jugdutt, B. I., & Menon, V. (2003) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840300800307 · Cited by 13
Saul, S., Duprez, D. A., Zhong, W., Grandits, G., & Cohn, J. N. (2012) · Journal of Human Hypertension · doi:10.1038/jhh.2012.54 · Cited by 13
Barrios, V., Escobar, C., Calderón, A., Echarri, R., Barrios, S., & Navarro‐Cid, J. (2009) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320309343596 · Cited by 13
Du, Z., Xing, L., Ye, N., Lin, M., & Sun, Y. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002652 · Cited by 13
Saunders, E., & Gavin, J. R. (2003) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2003.02181.x · Cited by 15
Kim, S., Ryu, K.-H., Lee, N.-H., Kang, J.-H., Kim, W.-S., Park, S. W., Lee, H., Kim, J., Ahn, Y., & Suh, S.-Y. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-461 · Cited by 15
Mehra, M. R., Uber, P. A., & Potluri, S. P. (2002) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200211000-00006 · Cited by 13
Karamyan, V. T., Tadevosyan, A., & MacLaughlin, E. J. (2011) · Patient Related Outcome Measures · doi:10.2147/prom.s8384 · Cited by 14
Postma, M. J., & de Zeeuw, D. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp352 · Cited by 16
Böger, C. A., Götz, A., Krüger, B., Hösl, M., Schmitz, G., Riegger, G. A. J., & Krämer, B. K. (2005) · PubMed · Cited by 15
Nitric Oxide, Atherosclerosis and the Clinical Relevance of Endothelial Dysfunction
Anderson, T. J. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7960-5_5 · Cited by 14
Egan, B. M., Gleim, G. W., & Panish, J. M. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x13040 · Cited by 16
Ferrario, C. M. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x10160 · Cited by 13
Podar, T., & Tuomilehto, J. O. (2002) · Drugs · doi:10.2165/00003495-200262140-00001 · Cited by 14
Managing cardiovascular risk in patients with metabolic syndrome
Bassand, J. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80003-7 · Cited by 15
Greathouse, M. (2002) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2002.02077.x · Cited by 13
Prevention of type 2 diabetes: An update
Farag, A., Karam, J. G., Nicasio, J., & McFarlane, S. I. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0032-4 · Cited by 14
Angiotensin II Receptor Blockers in Heart Failure
Patterson, J. H. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.2.173.32095 · Cited by 13
Recent Developments in the Assessment and Management of Hypertension: CHEP, ALLHAT and LIFE
Zarnke, K. B. (2003) · Cited by 12
The Role of Angiotensin Receptor Blockers in Diabetic Nephropathy
Sharma, A. M., & Weir, M. R. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.05.2289 · Cited by 14
Efficacy of Amlodipine and Olmesartan Medoxomil in Hypertensive Patients With Diabetes and Obesity
Punzi, H. A., Shojaee, A., Waverczak, W. F., & Maa, J. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00422.x · Cited by 12
Statistics‐based research – a pig in a poke?
Penston, J. G. (2011) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2011.01717.x · Cited by 12
Palanisamy, A. P., Schiltz, C. E., Pilch, N. A., Hunt, K. J., Nadig, S. N., Dowden, J. E., McGillicuddy, J. W., Baliga, P. K., Chavin, K. D., & Taber, D. J. (2014) · Blood Pressure · doi:10.3109/08037051.2014.934527 · Cited by 12
García‐Donaire, J. A., Segura, J., Cerezo, C., & Ruilope, L. M. (2011) · Blood Pressure · doi:10.3109/08037051.2011.602878 · Cited by 14
Sica, D. A., & Weber, M. A. (2002) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.01099.x · Cited by 14
Management of hypertension in low and middle income countries: Challenges and opportunities
Mohan, S., Campbell, N. R. C., & Chockalingam, A. (2005) · Global Heart · doi:10.1016/j.precon.2006.04.001 · Cited by 18
Nyström, T., Holzmann, M. J., & Sartipy, U. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002411 · Cited by 13
Hypertension and Diabetes Mellitus
Mugo, M. N., Stump, C. S., Rao, P. G., & Sowers, J. R. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3053-9.50040-8 · Cited by 15
Ravid, M., & Rachmani, R. (2005) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2004.10.016 · Cited by 12
Mengden, T., Uen, S., & Bramlage, P. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5549 · Cited by 14
Goupil, R., Dupuis, D., Troyanov, S., Madore, F., & Agharazii, M. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000978 · Cited by 13
A Systematic Approach to Managing Hypertension and the Metabolic Syndrome in Primary Care
Bestermann, W. H., Lackland, D. T., Riehle, J. E., & Egan, B. M. (2004) · Southern Medical Journal · doi:10.1097/01.smj.0000129923.83896.cc · Cited by 12
Major benefits from cholesterol-lowering in patients with diabetes
Lindholm, L. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13672-0 · Cited by 12
Self-citationManagement of hypertension in elderly diabetic patients
Blicklé, J. F. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(05)73656-9 · Cited by 14
Treatment of hypertension in metabolic syndrome: Implications of recent clinical trials
Makaryus, A. N., Akhrass, P., & McFarlane, S. I. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0037-2 · Cited by 14
The role of blood pressure lowering before and after stroke
Donnan, G. A., Davis, S. M., & Thrift, A. G. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200302000-00011 · Cited by 38
Capítulo 7 – Tratamento Medicamentoso
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160157 · Cited by 15
Cooper, T. E., Teng, C., Tunnicliffe, D. J., Cashmore, B. A., & Strippoli, G. F. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007751.pub3 · Cited by 15
Management of the Patient With Diabetes and Coronary Artery Disease: A Contemporary Review
Raymond, T. E., Raymond, R. E., & Lincoff, A. M. (2013) · Future Cardiology · doi:10.2217/fca.13.22 · Cited by 11
Drug treatment of hypertension in older patients with diabetes mellitus
Yandrapalli, S., Pal, S., Nabors, C. C., & Aronow, W. S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1456529 · Cited by 15
Fudim, M., Liu, P. R., Shrader, P., Blanco, R. G., Allen, L. A., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Hylek, E. M., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007987 · Cited by 11
Sukumaran, V., Gurusamy, N., Yalcin, H. C., & Venkatesh, S. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02651-x · Cited by 15
Remission of Type 2 Diabetes Mellitus by Ileal Interposition with Sleeve gastrectomy
Kota, S. K., Ugale, S. M., Gupta, N., Naik, V., Kota, S. K., Kumar, K. H., & Modi, K. D. (2012) · Intern J Endocrinol Metab · doi:10.5812/kowsar.1726913x.2782 · Cited by 12
Management of Cardiovascular Disease in the Renal Transplant Recipient
Rigatto, C. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2005.03.008 · Cited by 13
Bugiardini, R., Pavasović, S., Yoon, J., van der Schaar, M., Kedev, S. A., Vavlukis, M., Vasiljević, Z., Bergami, M., Miličić, D., Manfrini, O., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100548 · Cited by 13
Enteropathy-associated T-cell lymphoma presenting with eosinophilia.
Hovenga, S., de Graaf, H., Joosten, P., van den Berg, G. A., Storm, H., Langerak, A. W., Kluin, P. M., & Kibbelaar, R. (2003) · PubMed · Cited by 11
Linking diabetes and atherosclerosis
Candido, R., Bernardi, S., & Allen, T. J. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.46 · Cited by 13
CALCIUM CHANNEL BLOCKERS IN THE PREVENTION OF END STAGE RENAL DISEASE: A REVIEW
Derwa, A., Peeters, P. C., & Vanholder, R. C. (2004) · Acta Clinica Belgica · doi:10.1179/acb.2004.007 · Cited by 13
Microalbuminuria and diabetic cardiovascular disease
MacIsaac, R. J., & Cooper, M. E. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0005-2 · Cited by 13
Srinivasan, V., Sivaramakrishnan, H., & Karthikeyan, B. (2012) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2012.03.022 · Cited by 11
Dawson, A., Rana, B. S., Pringle, S. D., Donnelly, L. A., Morris, A. D., & Struthers, A. D. (2004) · Journal of Hypertension · doi:10.1097/01.hjh.0000125408.50839.b8 · Cited by 11
Yu, F., Chen, R., Takahashi, T., Sumino, H., Morimoto, S., Nakahashi, T., Iwai, K., Matsumoto, M., & Kanda, T. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.07.130 · Cited by 12
Endothelium-dependent vasomotor effects of telmisartan in isolated rat femoral arteries
Siarkos, I., Urso, V., Sinagra, T., Drago, F., & Salomone, S. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.10.010 · Cited by 12
Update of treatment of heart failure with reduction of left ventricular ejection fraction
Aronow, W. S. (2016) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2016.63002 · Cited by 12
Kabutoya, T., Hoshide, S., & Kario, K. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa092 · Cited by 11
Intake of isoflavones reduces the risk of all-cause mortality in middle-aged Japanese
Nakamoto, M., Otsuka, R., Tange, C., Nishita, Y., Tomida, M., Imai, T., Sakai, T., Ando, F., & Shimokata, H. (2021) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00890-w · Cited by 13
Valsartan Amlodipine Randomized Trial (VART): Design, Methods, and Preliminary Results
NAKAYAMA, K., Kuwabara, Y., Daimon, M., Shindo, S., Fujita, M., Narumi, H., MIZUMA, H., & Komuro, I. (2008) · Hypertension Research · doi:10.1291/hypres.31.21 · Cited by 11
Fortschritte in der Prävention des Typ-2-Diabetes
Schernthaner, G. (2003) · Wiener klinische Wochenschrift · doi:10.1007/bf03040499 · Cited by 14
Hypertension: A Review and Rationale of Treatment
Copley, J. B., & Rosario, R. (2005) · Disease-a-Month · doi:10.1016/j.disamonth.2005.10.004 · Cited by 11
Staessen, J. A., Thijs, L., Li, Y., Kuznetsova, T., Richart, T., Wang, J., & ger, W. B. (2007) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3281eb8e8d · Cited by 11
Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan
Iwashima, Y., Okada, M., Haneda, M., & Yoshida, T. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.03.032 · Cited by 11
Antihypertensives in people with gout or asymptomatic hyperuricaemia
Ruilope, L. M. (2012) · BMJ · doi:10.1136/bmj.d7961 · Cited by 11
Metadata
- Authors
- Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., & Snapinn, S.
- Affiliations
- University Hospital of Umeå (SE)
- Glostrup Hospital (DK)
- Sahlgrenska University Hospital (SE)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- University of Michigan (US)
- Oslo University Hospital (NO)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lindholm, Lars H
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 1004-1010
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1982920623
- Cited by
- 1,560
- References
- 31
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 15 · 2022: 17 · 2021: 18 · 2020: 29 · 2019: 16 · 2018: 28 · 2017: 40 · 2016: 40 · 2015: 41 · 2014: 48 · 2013: 58 · 2012: 58
- FWCI
- 129.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- losartan, atenolol, hypertension, diabetes mellitus, left ventricular hypertrophy, cardiovascular morbidity, cardiovascular mortality, antihypertensive drugs, ACE inhibitors, beta-blockers, LIFE trial, stroke, myocardial infarction, all-cause mortality, blood pressure reduction, Framingham risk score, electrocardiogram
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged, Regression Analysis, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.